Author, year | Study design | Â | Â | Â | Â | Â | Associated phenotype(s) | Associated variant(s) | Ref |
---|---|---|---|---|---|---|---|---|---|
Study approach | No. of osteosarcoma patients | Follow-up time | Ethnicity; nationality | Investigated number of variants and genes | Investigated phenotypes | ||||
Gong et al., 2021 | Pathway approach | 7 of 80 | NS | NS; Chinese | 23 variants in 15 drug metabolizing and transport genes | Mucositis | Mucositis | ABCB1 rs1128503 | [26] |
ABCB1 rs1045642 | |||||||||
MTHFR rs1801133 | |||||||||
Hattinger et al., 2016 | Pathway approach | 57 | NS | NS; Italian | 45 variants in 31 drug metabolism and transport genes | Leukopenia, thrombocytopenia, red blood cell transfusion, platelet transfusion, hepatotoxicity | Leukopenia | ABCC2 rs2273697a | [35] |
MTHFR rs1801131a | |||||||||
Thrombocytopenia | ABCC2 rs2273697a | ||||||||
XPD rs1799793a | |||||||||
Hepatotoxicity | ABCB1 rs1128503a | ||||||||
ABCC2 rs2273697a | |||||||||
GGH rs1800909HWa | |||||||||
Hegyi et al., 2017 | Pathway approach | 59 | NS | NS; Hungarian | 29 variants in ABCB1, ABCC1, ABCC2, ABCC3, ABCC10, ABCG2, GGH, SLC19A1, NR1I2 | Leukocyte/ neutrophil granulocyte count | Myelotoxicity | ABCC2 rs2273697a | [60] |
ABCC2 rs3740066a | |||||||||
NR1I2 rs3732361a | |||||||||
NR1I2 rs3814058a | |||||||||
NR1I2 rs6785049a | |||||||||
Hepatotoxicity | NR1I2 rs3732361a | ||||||||
NR1I2 rs3814058a | |||||||||
NR1I2 rs6785049a | |||||||||
Hurkmans et al., 2020 | ADME panel | 113 | NS | Caucasian; Dutch, Spanish, Australian | 1936 variants in 231 ADME genes | Creatinine, ALAT, ASAT, hemoglobin, thrombocyte, leukocyte and neutrophil counts | Thrombocyte counts | CYP2B6 rs4803418 | [61] |
CYP4F8 rs4808326 | |||||||||
CYP2B6 rs4803419 | |||||||||
Meijer et al., 2021 | GWAS | Stage 1: 208 (of 390) | Cases: 0.4 (0–3) years Controls: 0.3 (0–2.5) | NS; European | NS | Ototoxicity | Ototoxicity | TCERGL1 rs893507a | [25] |
Stage 2: 49 (of 192) | Cases: 0.7 (0.2–11.4) Controls: 0.8 (0.1–16.2) | NS; Canadian |  |  |  |  | |||
Stage 3: 111 (of 188) | Cases: 1.6 (0–17.2) Controls 1.7 (0–11.8) | NS; European |  |  |  |  | |||
Windsor et al., 2012 | Pathway approach | 58 | 41 (12–93) months | Caucasian: 41 | 36 variants in 21 pharmacological pathway genes of MAP | Anemia, leucopenia, myelo-suppression, GFR, infection | Leucopenia | ERCC1 rs3212986a | [37] |
Afro-Caribbean: 8 | GSTP1 rs1695a | ||||||||
Indian/Asian: 9 | ABCC2 rs17222723a | ||||||||
Anemia | MTHFD1 rs2236225a | ||||||||
MTHFR rs1801131a | |||||||||
CYBA rs4673a | |||||||||
Infection | XPC rs2228001a | ||||||||
Nephrotoxicity | ERCC2 rs13181a | ||||||||
MTHFR rs1801133a |